Results, Reports and Publications
Latest Results
Clariant delivers resilient performance in challenging environment
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
- Q1 2026 sales decreased by 2 % in local currencies1 to CHF 918 million with the Middle East conflict impacting Catalyst volumes and portfolio pruning affecting Care Chemicals; 0.5 % decline excluding portfolio pruning
- Q1 2026 EBITDA margin before exceptional items of 17.5 % decreased by 130 basis points compared to a strong Q1 2025 mainly due to the Middle East conflict and a one-off impacting Catalysts
- Q1 2026 free cash flow conversion improved by 12 percentage points to 54 % (LTM basis), achieved through effective net working capital management and continued disciplined Capex
- On track to achieve the remaining CHF 30 million of the total CHF 80 million performance improvement program savings (Investor Day 2024) already in 2026, with CHF 9 million achieved in the first quarter
- Guidance 2026 remains unchanged while Middle East conflict particularly impacting demand in our Catalysts business, causing increasing input costs, and overall elevated uncertainty and volatility
“In the first quarter of 2026, Clariant delivered flat underlying sales, excluding the effects of our proactive portfolio pruning measures. The EBITDA margin of 17.5 % before exceptional items was 130 basis points lower year on year against a strong comparison base, with the Middle East conflict impacting our Catalysts business, in particular. We achieved a twelve-percentage point improvement in free cash flow conversion to 54 % and are on track to deliver full run-rate savings of CHF 80 million from our performance improvement program by year end. This is one year ahead of our commitment. We continued to drive innovation with an increased innovation sales ratio of 19.9 % and we received six prestigious innovation awards at in-cosmetics Global in Paris and Chinaplas in Shanghai,” said Conrad Keijzer, Chief Executive Officer of Clariant.
“Our guidance for 2026 remains unchanged, with sales expected to be around 2025 levels in local currency and an EBITDA margin of around 18 % before exceptional items. The Middle East conflict is mainly impacting our Catalysts customers in the Middle East and Asia, with sales now expected to be below the prior year. At the same time, we expect growth in Adsorbents & Additives, as well as continued slight underlying growth in Care Chemicals, despite the Middle East impacts in Oil Services and increasing risks on the overall demand environment. To mitigate the inflation in raw materials and energy, we activated our proven value-based price management and further continue our focus on cost initiatives. By leveraging our global network and employing proactive logistics we provide continued supply for our customers,” Conrad Keijzer added.
1 All references to local currency growth, pricing, volumes, and scope exclude the impact from hyperinflation countries Argentina and Türkiye. All references to currency include a net impact from hyperinflation countries Argentina and Türkiye.
Read more
Results Center
Please use the Results Center to find Clariant’s financial results and associated documents as published in the last five years
Q1 Q2 Q3 Q4 Date 29 April 2025 31 July 2025 30 October 2025 26 February 2026 Quiet Period as of 10 April as of 9 July as of 8 October as of 19 January 2026 Media Release EN EN EN EN Analyst Presentation EN EN EN EN Webcast Replay Audio recording MP3 MP3 MP3 MP3 Transcript EN EN EN EN Financial Review / HY Report EN - XLS EN - XLS Annual Report EN
Q1 Q2 Q3 Q4 Date 30 April 2024 30 July 2024 29 October 2024 28 February 2025 Quiet Period as of 11 April as of 10 July as of 9 October as of 10 January 2025 Media Release EN EN EN EN Analyst Presentation EN EN EN EN Webcast Audio recording MP3 MP3 MP3 MP3 Transcript EN EN EN EN Financial Review / HY Report EN - XLS EN - XLS Annual Report EN
Q1 Q2 Q3 Q4 Date 5 May 2023 28 July 2023 30 October 2023 29 February 2024 Quiet Period as of 17 April as of 10 July as of 10 October as of 15 January Media Release EN — DE EN — DE EN — DE EN — DE Analyst Presentation EN EN EN EN Webcast Audio recording MP3 MP3 MP3 MP3 Transcript EN EN EN EN Financial Review / HY Report EN EN — XLS Annual Report EN
Q1 Q2 Q3 Q4 Date 15 June 2022 28 July 2022 27 October 2022 2 March 2023 Quiet Period as of 11 July as of 10 October as of 17 February Media Release EN — DE EN — DE EN — DE EN — DE Analyst Presentation EN EN EN EN Webcast Audio recording MP3 MP3 MP3 MP3 Transcript
EN Financial Review / HY Report EN EN Annual Report EN
Conferences and Roadshows
Clariant's Management and Investor Relations Team regularly participates in Conferences and Roadshows. Below you can find an overview of the presentations provided at such events in the last two years.
For an overview of upcoming events, please refer to the Financial Calendar.
